S econdary dystonia is a prominent feature in 15%-25% of patients with CP and is often refractory to medical therapy. 4, 18 Secondary generalized dystonia is also a common sequela of traumatic and anoxic brain injury. 5, 18 Narayan et al. 19 first described the use of intrathecal baclofen to treat secondary generalized dystonia in 1991. Since then, multiple studies have demonstrated its efficacy for children with secondary dystonias. 4, 5, 8, 10, 18, 21, 26, 27 Albright and colleagues 5 demonstrated that a more cranial location of the catheter tip was associated with improved efficacy in secondary generalized dystonia. Electrophysiological studies have suggested cerebral sites of baclofen action in patients with dystonia, whereas the sites of action in spasticity are primarily spinal. 9, 23 Albright 1 was the first to report the intraventricular administration of baclofen in 2 children with mixed spasticity and dystonia, with mixed results. On the basis of these observations, he performed experiments in dogs that demonstrated the safety of long-term intraventricular baclofen administration. 2 A larger series of 10 patients with severe dystonia, including 9 with secondary generalized dystonia, demonstrated good results in all but 2 patients in whom high-dose intrathecal baclofen treatment had failed previously. 6 To date, 13 cases treated with intraventricular baclofen infusion have been reported. 1, 6, 25 We report the use of intraventricular baclofen in 3 additional cases and describe a novel surgical technique. All patients had severe, secondary generalized dystonia as the primary indication for baclofen therapy. The rationale for using intraventricular baclofen was based on data supporting improved efficacy of intraspinal baclofen for dystonia with a more rostral catheter tip, 5 the cortical location of pharmacological targets in dystonic patients, 9, 23 the reported safety and efficacy of long-term intraventricular baclofen administration, 1,2,6,25 and our institutional experience of poor control of dystonic symptoms with intraspinal catheters.
Methods

Patient Histories
Three children with a history of secondary generalized dystonia and spasticity (mean age 8.8 years, range 3.7-17 years) underwent placement of an intraventricular catheter and subfascial placement of a programmable pump for the continuous administration of baclofen (Table 1) Continuous infusion of baclofen is a treatment option for severe generalized dystonia. Catheter insertion within the third ventricle has been described as an alternative to standard intrathecal placement to maximize intracranial concentrations of baclofen. The authors describe their experience with a novel technique for stereotactic endoscopic insertion of baclofen infusion catheters in the third ventricle in 3 patients with severe secondary generalized dystonia. Insertion was successful in all 3 patients, and all of them experienced significant improvement in dystonia scores on the Barry-Albright Dystonia Scale. Follow-up ranged from 5.5 to 7 months (mean 6 months), and no mechanical complications or CSF leaks were observed. The stereotactic endoscopic insertion of a baclofen infusion catheter into the third ventricle appears to be a safe method for continuous intraventricular baclofen infusion in patients with generalized secondary dystonia. trial consisting of a single intrathecal baclofen bolus dose of 100 μg (Case 1) or 75 μg (Case 2) delivered via lumbar puncture, with significant improvement in muscle tone. One patient (Case 3) was previously treated with continuous infusion of intrathecal baclofen.
The first patient was a boy whose age was 5 years and 10 months, in whom adrenoleukodystrophy and developmental delay had been diagnosed. He had severe generalized dystonia. The patient in the second case, who was 3 years and 7 months old, had a near-drowning event resulting in cardiac arrest. Despite successful resuscitation, he suffered severe hypoxic-ischemic encephalopathy and bilateral thalamic infarctions. He subsequently developed quadriparesis and dystonia characterized by intermittent axial posturing, including opisthotonos. He underwent placement of the intraventricular catheter and pump 1 month after his accident. The third patient, a 17-year-old boy with a history of CP, spastic quadriparesis, and prominent dystonia, was previously treated with intrathecal baclofen infusion for 4 years and 10 months. Dystonic posturing included intermittent hyperextension and rotation of the neck and torso that significantly interfered with his feeding and overall care. Some improvement in truncal dystonia was achieved with an intrathecal infusion rate of 852 μg/day via a high-thoracic catheter; however, his cervical dystonia remained poorly controlled.
Surgical Procedure
After the induction of general anesthesia, the patients were positioned supine with a gel roll elevating the right shoulder and the head turned to the left and secured on a doughnut pillow. Next, the Stealth AxiEM electromagnetic navigation system (Medtronic, Inc.) was registered. A straight incision was marked overlying the planned right frontal entry point in the approximate location of the Kocher point. The frontal horn of the lateral ventricle at the foramen of Monro was selected as the target. A right retroauricular incision was marked to secure the tunneled catheter. A standard right periumbilical abdominal incision was also marked for subfascial implantation of a 20-or 40-ml baclofen pump, as previously described. 15 To minimize the risk of infection, 30 mg/kg of cefazolamide was administered intravenously prior to the incision, chlorhexidine was used to prepare the skin, and all surgical team members were fully scrubbed and double gloved. 14 First, the right frontal and retroauricular incisions were sharply opened, and a subgaleal tract was tunneled with a shunt passer. Next, we tunneled an 8709SC baclofen infusion catheter (Medtronic, Inc.) from the caudal to the cranial regions and wrapped it in bacitracinsoaked laparotomy sponges. Through a standard 7-mm bur hole at the right frontal entry point, we made a cruciate opening in the dura mater. An electromagnetic stylet (Medtronic) was placed within a 10-Fr blunt, peel-away introducer (3.2-mm internal diameter; Aesculap). The stylet was passed from the entry to the target in the lateral ventricle by using AxiEM stereotactic navigation. After the stylet was removed, the introducer was peeled back and secured to the drapes with staples.
Next, the Neuropen endoscope (Medtronic) was advanced through the introducer sheath, and the foramen of Monro was visualized. The infusion catheter was then passed through the bur hole and sheath into the lateral ventricle adjacent to the endoscope and, under endoscopic visualization, through the foramen of Monro into the third ventricle. The endoscope was then advanced through the foramen of Monro to confirm the final position of the catheter tip.
After the endoscope was withdrawn, the peel-away introducer sheath was removed, and the catheter was secured within the bur hole by using thrombin-soaked Gelfoam and fibrin tissue sealant. Subsequently, a Silastic anchor was used to secure the catheter more caudally to the galea beneath the retroauricular incision by using multiple 3-0 Nurolon sutures. After the periumbilical incision was opened and the subfascial pocket developed, the caudal end of the catheter was tunneled to the abdomen and secured to a 20-or 40-ml Synchromed II infusion pump (Medtronic). Before we connected the pump and catheter, we injected 10 mg of vancomycin and 4 mg of gentamicin into the catheter, as is our practice for CSF shunts. 22 All incisions were copiously irrigated with bacitracin and then closed in layers. The baclofen infusion was started at a rate of 50-100 mg/day. Postoperatively, the patients were observed overnight in the pediatric ICU because of concern for respiratory depression. 2 On the 1st postoperative day, all patients underwent CT scans of the head without contrast enhancement as well as lateral skull and anteroposterior skull, chest, and abdominal x-ray studies (Fig. 1) .
Results
In all 3 patients, insertion of the third ventricle catheter and programmable pump was successful. None of the patients experienced respiratory depression, and there were no perioperative complications. All 3 patients expe- Postoperative scores of 1-2 (cumulative scores of [10] [11] [12] were observed in all regions in all 3 patients, although the third patient is still undergoing regular dose adjustments and had variable control. During the follow-up period (range 5.5-7 months, mean 6 months), we observed no mechanical complications, CSF leaks, or symptoms of baclofen overdose. The first 2 patients were not previously treated with intrathecal baclofen, other than a single-bolus trial delivered via lumbar puncture. Therefore, intraventricular baclofen infusions were started at a rate of 50 mg/day, which is our convention when starting intrathecal baclofen infusion. In the first patient, this was increased over 1 month to 125 mg/day, and the last recorded dose was 235 mg/day. The second patient was increased from 50 to 200 mg/day over the course of 3 days to relieve severe dystonia, while being monitored in the pediatric ICU for respiratory depression. None was observed. The last recorded dose was 635 mg/day.
In the third patient, who was previously treated with an intrathecal baclofen infusion of 852 mg/day, the intraventricular infusion was started at 100 mg/day. This was increased over 3 days to 525 mg/day to treat severe neck dystonia, while being monitored in the pediatric ICU for respiratory depression. Again, this was not observed. The infusion was further increased over several months to a current dose of 980 mg/day. In all 3 patients, dose titration was individualized because of differences in patient age and patterns of dystonia.
Discussion
Further study is required to compare benefits and complications of intraventricular and intrathecal baclofen infusion in the treatment of secondary generalized dystonia; however, it appears that intraventricular baclofen infusion is a promising approach that may be performed with minimal risk. These 3 cases bring the total number of reported cases of intraventricular baclofen infusion to 16, including 13 for dystonia. 1, 6, 25 Presently available catheters are designed for intraspinal placement and are therefore flexible and require the use of an introducer for primary access to the ventricular system. Albright and Ferson 6 also described an endoscopic technique. In this report, we describe a combined stereotactic endoscopic approach through a smaller introducer (the 10-Fr vs 19-Fr size). The use of navigation together with endoscopic visualization, although more expensive, increases the safety profile of access to the third ventricle in patients who commonly have distorted intraventricular anatomy.
Intrathecal baclofen infusion is a well-established treatment for severe spasticity and secondary generalized dystonia, especially among children with CP or those who have suffered severe traumatic or anoxic brain injury. [3] [4] [5] 8, 12, [18] [19] [20] 26, 27 It has also been successfully applied to other movement disorders, including cervical and focal hand dystonia 10 as well as neuroleptic malignant syndrome. 25 Standard catheter placement is in the low thoracic spine.
17 Some authors have also described the use of cervical catheters in the context of previous spinal fusion, 10, 16 as a strategy to optimize efficacy in the upper extremities in quadriplegic spasticity, 17 and for the control of cervical dystonia. 10 The use of intraventricular baclofen infusion has rarely been described. 1, 6, 25 Specifically, it has been suggested as a strategy to improve secondary generalized dystonia by increasing the concentrations of baclofen in the intracranial subarachnoid space. 1, 6, 9, 23 It has also been used effectively for the treatment of refractory neuroleptic malignant syndrome. 25 All previous reports of intraventricular baclofen for dystonia have described catheter placement in the third ventricle to optimize symmetrical subarachnoid drug concentrations. 1, 6 Although intracranial catheter placement after hemispherectomy has been reported as a successful treatment for refractory neuroleptic malignant syndrome in 1 patient, different catheter positions within the ventricular system (for example, lateral vs third) have not been compared in patients with dystonia, and the comparative efficacies of intraventricular versus intraspinal baclofen infusion remain unknown.
The long-term administration of intraventricular baclofen appears to be safe although dose-related toxicity, including respiratory depression and temperature lability, was demonstrated in dogs. 2 Complications are common with implanted baclofen infusion systems; in published reports they occur in between 5% and 40% of cases. 18, 26 Complications are more common in the pediatric population, 24 and some studies suggest a higher frequency in patients treated for dystonia. 26 It is possible that rarely reported complications of intrathecal baclofen, including amnesia, 13 may become more common with intraventricular delivery; however, if similar efficacy can be maintained with lower baclofen concentrations because of a higher concentration of the drug in the intracranial subarachnoid space proximal to cortical targets, perhaps these complications can be avoided. Given our small series with short follow-up, we have not observed catheter malfunction or acute baclofen withdrawal. We do not yet have the clinical experience with intraventricular infusion to determine whether acute baclofen withdrawal is more likely or more dangerous than what has been seen with long-term intraspinal infusion. Furthermore, we have no experience using this technique in patients with ventriculoperitoneal shunts, which would complicate attempts at intraventricular infusion.
Conclusions
We achieved significant improvement in dystonia as measured by Barry-Albright Dystonia Scale scores in all 3 of our patients, and similar results compared with previous reports of intraventricular baclofen 6 and intrathecal baclofen. 11 Stereotactic endoscopic placement of a third ventricle catheter for continuous infusion of intraventricular baclofen appears to be a safe and effective method that holds promise for the treatment of secondary generalized dystonia. Further study is required to determine the best candidates for this technique and to elucidate advantages in comparison with intrathecal baclofen administration.
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